207 related articles for article (PubMed ID: 34426249)
1. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
3. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.
De Clercq K; Xie F; De Wever O; Descamps B; Hoorens A; Vermeulen A; Ceelen W; Vervaet C
Sci Rep; 2019 Oct; 9(1):14881. PubMed ID: 31619730
[TBL] [Abstract][Full Text] [Related]
5. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
7. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
9. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
[TBL] [Abstract][Full Text] [Related]
10. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
[TBL] [Abstract][Full Text] [Related]
12. Nanog-mediated stem cell properties are critical for MBNL3-associated paclitaxel resistance of ovarian cancer.
Sun X; Diao X; Zhu X; Yin X; Cheng G
J Biochem; 2021 Sep; 169(6):747-756. PubMed ID: 33599261
[TBL] [Abstract][Full Text] [Related]
13. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
14. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
16. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer.
Lv W; Cheng L; Li B
Chem Pharm Bull (Tokyo); 2015; 63(2):68-74. PubMed ID: 25451039
[TBL] [Abstract][Full Text] [Related]
18. A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.
Pellegrini E; Multari G; Gallo FR; Vecchiotti D; Zazzeroni F; Condello M; Meschini S
Toxicol Appl Pharmacol; 2022 Jan; 434():115816. PubMed ID: 34856211
[TBL] [Abstract][Full Text] [Related]
19. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y
Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906
[TBL] [Abstract][Full Text] [Related]
20. Pleuromutilin Inhibits Proliferation and Migration of A2780 and Caov-3 Ovarian Carcinoma Cells and Growth of Mouse A2780 Tumor Xenografts by Down-Regulation of pFAK2.
Zhang B; Ma X; Li Y; Li S; Cheng J
Med Sci Monit; 2020 Feb; 26():e920407. PubMed ID: 32041931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]